A. Hay

Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial.

P. Vasey, S. Kaye, J. Paul, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.

Alan Gordon, James Paul, Gordon C Jayson, 2004, Journal of the National Cancer Institute.

Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial.

R. Glasspool, P. Vasey, S. Kaye, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Aggressive surgery and ovarian cancer - Reply

P. Vasey, S. Kaye, J. Paul, 2006 .

The prognostic significance of the CA125 nadir in patients that achieve a CA125 response.

P. Vasey, N. Reed, J. Paul, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomised comparison of treosulfan and carboplatin in patients with ovarian cancer: a study by the Scottish Gynaecological Cancer Trials Group (SGCTG).

C. Poole, S. Kaye, J. Graham, 2006, European journal of cancer.